| scholarly article | Q13442814 |
| P50 | author | Wieslaw Jedrzejczak | Q9373502 |
| Krzysztof Warzocha | Q11749787 | ||
| Hermann Einsele | Q1610986 | ||
| Jesús San Miguel | Q5930658 | ||
| Joan Bladé | Q87885218 | ||
| Lugui Qiu | Q88013660 | ||
| Wenming Chen | Q88054219 | ||
| Peter Gimsing | Q89084681 | ||
| Jonathan L Kaufman | Q89455185 | ||
| Kwee L Yong | Q90710845 | ||
| Vania Hungria | Q91273829 | ||
| Robert Schlossman | Q114300414 | ||
| Jamie D Cavenagh | Q114442098 | ||
| Thanyaphong Na Nakorn | Q117252337 | ||
| Noppadol Siritanaratkul | Q117252338 | ||
| Claudia Corrado | Q117252340 | ||
| Bourras-Rezki Bengoudifa | Q117252342 | ||
| Florence Binlich | Q117252344 | ||
| Athanasios Dimopoulos | Q26338766 | ||
| Paolo Corradini | Q37838318 | ||
| Javier de la Rubia | Q42814411 | ||
| Hareth Nahi | Q56421057 | ||
| Meral Beksac | Q57078421 | ||
| Hans Salwender | Q57159225 | ||
| Monika Sopala | Q60140073 | ||
| Ashraf Elghandour | Q60324814 | ||
| Enrique M Ocio | Q60324819 | ||
| Sagar Lonial | Q66431075 | ||
| Paul G. Richardson | Q87712102 | ||
| Philippe Moreau | Q87734443 | ||
| P2093 | author name string | Je-Jung Lee | |
| Sung-Soo Yoon | |||
| Jae Hoon Lee | |||
| Jian Hou | |||
| Andreas Günther | |||
| Suporn Chuncharunee | |||
| Ming-Chung Wang | |||
| Sang Kyun Sohn | |||
| Richard LeBlanc | |||
| Tontanai Numbenjapon | |||
| Daryl Tan | |||
| Stefano Pulini | |||
| Darrell White | |||
| Tatiana Shelekhova | |||
| Ljupco Veskovski | |||
| P2860 | cites work | International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation | Q27002668 |
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 | ||
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Q33394981 | ||
| Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R | Q33401216 | ||
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma | Q33402536 | ||
| PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma | Q33409825 | ||
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Q33410172 | ||
| Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. | Q33410225 | ||
| Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study | Q33410481 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma | Q37379984 | ||
| Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges | Q37432654 | ||
| European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma | Q37552008 | ||
| Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma | Q37954600 | ||
| Association of response endpoints with survival outcomes in multiple myeloma | Q38122624 | ||
| In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma | Q39768627 | ||
| Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells | Q42156460 | ||
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. | Q42921022 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma | Q83358859 | ||
| P433 | issue | 11 | |
| P921 | main subject | placebo | Q269829 |
| dexamethasone | Q422252 | ||
| multicenter clinical trial | Q6934595 | ||
| phase III clinical trial | Q42824827 | ||
| P1104 | number of pages | 12 | |
| P304 | page(s) | 1195-1206 | |
| P577 | publication date | 2014-09-18 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | |
| P478 | volume | 15 |
| Q39147132 | A chemical probe toolbox for dissecting the cancer epigenome |
| Q28067148 | A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma |
| Q40763491 | A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma |
| Q30239781 | A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival |
| Q37705920 | A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma |
| Q47584543 | A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas |
| Q89777245 | A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma |
| Q88364699 | A selective histone deacetylase inhibitor for myeloma |
| Q37210896 | AACR Cancer Progress Report 2015 |
| Q26739689 | Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies |
| Q38630472 | Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma |
| Q36000415 | Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party |
| Q36751751 | An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts |
| Q38765451 | An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma |
| Q38561373 | An update in treatment options for multiple myeloma in nontransplant eligible patients |
| Q100395010 | Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf |
| Q90029028 | Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist |
| Q92276353 | Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes |
| Q90185321 | Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials |
| Q48272362 | Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface recepto |
| Q42378528 | BET inhibitors as novel therapeutic agents in breast cancer. |
| Q64978883 | Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study. |
| Q92812162 | Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma |
| Q40047253 | Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study |
| Q93144918 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later |
| Q52686509 | Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. |
| Q90012167 | Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial |
| Q52812971 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. |
| Q33428423 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study |
| Q37652953 | Carfilzomib boosted combination therapy for relapsed multiple myeloma |
| Q38989789 | Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma |
| Q49931866 | Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study |
| Q92233485 | Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials |
| Q93269619 | Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib |
| Q91756067 | Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner |
| Q33443179 | Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat |
| Q90293639 | Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy |
| Q26795696 | Clinical characteristics of patients with relapsed multiple myeloma |
| Q26747768 | Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor |
| Q26745930 | Clinical use and applications of histone deacetylase inhibitors in multiple myeloma |
| Q60920589 | Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study |
| Q49949477 | Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. |
| Q59807925 | Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis |
| Q26782868 | Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title) |
| Q36480589 | Cost of Treatment for Relapsed/Refractory Multiple Myeloma |
| Q64098082 | Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis |
| Q47348957 | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. |
| Q38672091 | Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma |
| Q38658649 | Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. |
| Q38412189 | Current therapeutic strategies for multiple myeloma |
| Q38271032 | Current treatment landscape for relapsed and/or refractory multiple myeloma |
| Q38959138 | Current treatments for renal failure due to multiple myeloma |
| Q26749421 | DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics |
| Q52676395 | DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. |
| Q60922662 | DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling |
| Q59797151 | Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR |
| Q38996881 | Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma |
| Q33438321 | Deacetylase inhibitors: an advance in myeloma therapy? |
| Q89222569 | Death by a thousand cuts: the slow demise of chemotherapy |
| Q36572408 | Dinutuximab and Panobinostat |
| Q36178810 | Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma |
| Q92771675 | EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies |
| Q86915321 | ENDEAVOR to change treatment for multiple myeloma? |
| Q36494358 | Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations |
| Q33432845 | Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review |
| Q104268535 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study |
| Q33443417 | Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. |
| Q92298135 | Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials |
| Q64972393 | Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. |
| Q41694198 | Emerging drugs and combinations to treat multiple myeloma |
| Q92150213 | Emerging epigenetic-modulating therapies in lymphoma |
| Q47340203 | Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. |
| Q50330020 | Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance |
| Q55433291 | Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. |
| Q28072370 | Epigenetic Therapeutics: A New Weapon in the War Against Cancer |
| Q38895512 | Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. |
| Q38838643 | Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors |
| Q39261435 | Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma |
| Q48236958 | Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma. |
| Q39137683 | Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma |
| Q41064275 | Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy |
| Q38275276 | Epigenetic targets for novel therapies of lung diseases |
| Q39009379 | Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives |
| Q26773803 | Epigenetic treatment of solid tumours: a review of clinical trials |
| Q38542620 | Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs? |
| Q35726371 | Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update |
| Q38770916 | Epigenetics: A primer for clinicians |
| Q35809982 | Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. |
| Q42384490 | Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. |
| Q27026478 | Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies |
| Q26771331 | Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity |
| Q53099556 | Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma. |
| Q93082000 | Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network |
| Q52724347 | Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. |
| Q64928553 | HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. |
| Q43246885 | HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications |
| Q33834432 | HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells |
| Q38799515 | Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma |
| Q28082536 | Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy |
| Q37277238 | Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma |
| Q38813504 | Histone deacetylase inhibitors in multiple myeloma: from bench to bedside |
| Q59798907 | Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer |
| Q38572855 | Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review |
| Q36115680 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. |
| Q38910971 | In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. |
| Q49375952 | Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? |
| Q49244147 | Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. |
| Q33648440 | Individual patient oesophageal cancer 3D models for tailored treatment |
| Q42399891 | Innovations in treatment and response evaluation in multiple myeloma |
| Q92736173 | Insights into novel emerging epigenetic drugs in myeloid malignancies |
| Q46754093 | Integration of Novel Agents into the Care of Patients with Multiple Myeloma |
| Q58560605 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting |
| Q48126631 | Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma. |
| Q95661294 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis |
| Q92003943 | Key actors in cancer therapy: epigenetic modifiers |
| Q60952711 | Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data |
| Q38791113 | Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model |
| Q64099073 | Management of cardiovascular risk in patients with multiple myeloma |
| Q38874675 | Management of high-risk Myeloma: an evidence-based review of treatment strategies |
| Q49989003 | Management of multiple myeloma in the relapsed/refractory patient. |
| Q38896473 | Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. |
| Q47283493 | Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond |
| Q38681463 | Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group |
| Q38900024 | Managing renal complications in multiple myeloma |
| Q38725415 | Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib |
| Q39185604 | Mechanisms of Resistance in Multiple Myeloma |
| Q38860769 | Mechanisms of action and resistance for multiple myeloma novel drug treatments |
| Q64065815 | Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase |
| Q26768653 | Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment |
| Q47423761 | Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development |
| Q38756800 | Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes |
| Q103723880 | Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance |
| Q90544939 | Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled |
| Q45057327 | Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients |
| Q55476446 | Multiple Liver Nodules Mimicking Metastatic Disease as Initial Presentation of Multiple Myeloma. |
| Q89682913 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance |
| Q55119496 | Multiple Myeloma: Diagnosis and Treatment. |
| Q64883977 | Multiple Myeloma: Updates on Diagnosis and Management. |
| Q100316249 | Multiple myeloma current treatment algorithms |
| Q36725401 | Multiple myeloma in the marrow: pathogenesis and treatments. |
| Q37623809 | Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management |
| Q58565204 | Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management |
| Q37394605 | Multiple myeloma: patient outcomes in real-world practice |
| Q36470699 | Myeloma today: Disease definitions and treatment advances |
| Q47625488 | NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. |
| Q45043445 | NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments |
| Q48269862 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study |
| Q64901832 | Navigating the treatment landscape in multiple myeloma: which combinations to use and when? |
| Q89777946 | Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients |
| Q55283646 | New Treatment Strategies Making an Impact in Multiple Myeloma. |
| Q38598891 | New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib |
| Q28071551 | New investigational drugs with single-agent activity in multiple myeloma |
| Q38673764 | New pharmacotherapy options for multiple myeloma |
| Q58798742 | Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation |
| Q38981247 | Next-generation multiple myeloma treatment: a pharmacoeconomic perspective |
| Q39234159 | Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics |
| Q51761449 | Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults? |
| Q51188342 | Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). |
| Q38764510 | Novel therapeutic approaches in chondrosarcoma. |
| Q45873027 | Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives |
| Q47125228 | Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells |
| Q42046604 | Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study |
| Q38780843 | Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. |
| Q39280492 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial |
| Q38765760 | PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future |
| Q36848015 | Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma |
| Q33426983 | Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma |
| Q36109802 | Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data |
| Q37711782 | Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. |
| Q55064105 | Panobinostat and Multiple Myeloma in 2018. |
| Q38806260 | Panobinostat for the management of multiple myeloma |
| Q85350362 | Panobinostat for the treatment of multiple myeloma |
| Q26778674 | Panobinostat for the treatment of multiple myeloma: the evidence to date |
| Q38616807 | Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes |
| Q33428575 | Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial |
| Q89339834 | Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study |
| Q88761558 | Panobinostat in multiple myeloma |
| Q54682248 | Panobinostat plus bortezomib and dexamethasone for relapsed myeloma. |
| Q33428098 | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment |
| Q33443001 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. |
| Q38716460 | Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma |
| Q33430925 | Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma |
| Q38519497 | Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma |
| Q38269612 | Panobinostat: a review of trial results and future prospects in multiple myeloma |
| Q38403118 | Panobinostat: first global approval |
| Q41602673 | Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations |
| Q36703448 | Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas |
| Q37150016 | Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma |
| Q33437811 | Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. |
| Q33423168 | Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma |
| Q88402159 | Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease |
| Q49853764 | Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors |
| Q35571044 | Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma |
| Q43753697 | Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). |
| Q42940540 | Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial |
| Q92088331 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial |
| Q42425704 | Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma |
| Q37737800 | Posttransplant maintenance therapy in multiple myeloma: the changing landscape |
| Q52674773 | Potential of oncolytic viruses in the treatment of multiple myeloma. |
| Q38742700 | Practical Approaches to the Management of Dual Refractory Multiple Myeloma |
| Q41088379 | Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair |
| Q92572416 | Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant |
| Q52801394 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. |
| Q88797028 | Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies |
| Q53831599 | Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. |
| Q44694137 | Progress and Paradigms in Multiple Myeloma |
| Q48178842 | Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft |
| Q42581682 | Promising therapies in multiple myeloma |
| Q53752929 | Proteasome inhibitors in cancer therapy. |
| Q35408665 | Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy |
| Q33429115 | Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma |
| Q38967891 | RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma |
| Q36989576 | Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. |
| Q35750491 | Rational Combinations of Targeted Agents in AML |
| Q64242177 | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France |
| Q39690253 | Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices |
| Q28074521 | Recent advances in multiple myeloma: a Korean perspective |
| Q28070331 | Recent advances in understanding multiple myeloma |
| Q38757067 | Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. |
| Q92914144 | Relapsed refractory multiple myeloma: a comprehensive overview |
| Q53786308 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). |
| Q98177216 | Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors |
| Q38895216 | Rewiring the solid tumor epigenome for cancer therapy |
| Q33167710 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial |
| Q39040044 | Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma |
| Q37199772 | Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat |
| Q38455740 | Romidepsin for the treatment of non-Hodgkin's lymphoma |
| Q33438732 | Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study |
| Q58793830 | Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma) |
| Q39100317 | Safety issues and management of toxicities associated with new treatments for multiple myeloma. |
| Q39404809 | Safety of ixazomib for the treatment of multiple myeloma |
| Q26740359 | Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? |
| Q40454277 | Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. |
| Q42348465 | Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant |
| Q39013620 | Second primary malignancies in multiple myeloma: an overview and IMWG consensus |
| Q90669066 | Seeking Convergence and Cure with New Myeloma Therapies |
| Q36242646 | Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia |
| Q49068138 | Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming. |
| Q39027826 | Sequencing of nontransplant treatments in multiple myeloma patients with active disease |
| Q89777982 | Should minimal residual disease negativity be the end point of myeloma therapy? |
| Q38783055 | Sorafenib for the treatment of multiple myeloma. |
| Q38820565 | Specialty pharmacy for hematologic malignancies |
| Q50326769 | Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer |
| Q33441476 | Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma |
| Q38989377 | Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges. |
| Q38728585 | Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells? |
| Q38821103 | Targeting the cancer epigenome for therapy |
| Q28067187 | The Danish National Multiple Myeloma Registry |
| Q37150733 | The Diagnosis and Treatment of Multiple Myeloma |
| Q60960086 | The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response |
| Q47344797 | The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma |
| Q49349840 | The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). |
| Q38687570 | The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis |
| Q38873902 | The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. |
| Q28069789 | The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective |
| Q95642034 | The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer |
| Q58792448 | The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease |
| Q58718492 | The biological significance of histone modifiers in multiple myeloma: clinical applications |
| Q47375990 | The effect of novel therapies in high-molecular-risk multiple myeloma |
| Q91806716 | The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis |
| Q40153567 | The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia |
| Q30248534 | The next generation of novel therapies for the management of relapsed multiple myeloma |
| Q38685108 | The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma |
| Q47339695 | The proteasome and proteasome inhibitors in multiple myeloma |
| Q95650650 | The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |
| Q92356557 | The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond |
| Q55513961 | The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. |
| Q39177792 | Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy |
| Q47812117 | Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD). |
| Q64886671 | Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. |
| Q50281172 | Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses |
| Q38970597 | Treatment of Relapsed/Refractory Multiple Myeloma |
| Q64068728 | Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide |
| Q26749180 | Treatment of relapsed and refractory multiple myeloma |
| Q58729834 | Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis |
| Q39369772 | Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. |
| Q47552083 | Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent |
| Q38342281 | Treatment-related symptom management in patients with multiple myeloma: a review |
| Q30238893 | Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials |
| Q47770089 | Triplet vs. doublet drug regimens for managing multiple myeloma. |
| Q93189824 | Understanding Cancer Through the Lens of Epigenetic Inheritance, Allele-Specific Gene Expression, and High-Throughput Technology |
| Q59798196 | Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma |
| Q92603982 | Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective |
| Q33440007 | Update on the optimal use of bortezomib in the treatment of multiple myeloma |
| Q50166078 | Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. |
| Q92218684 | Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma |
| Q92276379 | Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma |
| Q38826861 | VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach |
| Q38970612 | Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment |
| Q38733592 | Which therapies will move to the front line for multiple myeloma? |
| Q52817414 | [Multiple myeloma : What has been confirmed in therapy?] |
Search more.